Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Rising liability awards

Asia is no longer the benign liability environment that it once was. Michael Griffiths, regional director of healthcare at Aon Singapore, explains why.

Imagine you are walking along a footpath in a suburban street somewhere in Asia. Not far ahead of you is a woman on a bicycle, riding on the same footpath. As she rides towards you, a bundle of overhead cables from an adjacent building site falls suddenly on to the street and hits the cyclist, knocking her to the ground.

You rush forward to assist, as do workers from the building site, and everyone is relieved to discover that the cyclist has not been seriously hurt. She is taken to hospital for a check-up, perhaps some treatment for cuts and bruises, but overall it seems that she has had a lucky escape. You would imagine that the owners of the building site will cover the cost of her check-up, repairs to her bicycle, and possibly offer a small apology gift, and that would be the end of the matter.

If this had happened in Australia or the US where people tend to be more litigious, the courts may award higher damages, but here in Asia, people generally do not like to sue, and the courts are generally far more conservative. Well, maybe they used to be, but times have changed.

On 15 October 2009, Ms Siew Pick Chiang, a 42 year-old woman, was cycling along a public path in Singapore, when she was struck by a bundle of overhead cables that had fallen from a building site. Ms Siew suffered only minor physical injuries, but the post-traumatic stress disorder she developed following the accident was so serious that she was hospitalised on at least 18 occasions, and at one stage remained in hospital for over two years. In 2012, she brought legal action against an engineering and construction firm, the main contractor of the building site, seeking damages of S$26 million (US$18.3 million). This amount included over S$13.6 million in medical costs alone, as well as claims for the cost of care givers, loss of income, and S$1.25 million in taxi fares.  

On 1 December last year, the Singapore High Court handed down its judgment. The defendant was found to be fully liable for the injuries suffered by Ms Siew, and was ordered to pay a total of S$8.645 million in damages. This represents the largest ever personal accident award made by the Singapore Courts, nearly S$6 million higher than the previous high water mark.

In our view, this case represents only the latest example of a much wider trend in Asia – that increasing amounts of damages are being awarded by courts.

An award of damages tends to reflect, among other things, the cost of living in the country where it is made. In Asian countries such as Singapore, Japan, Hong Kong, and Korea, the cost of living is now amongst the highest in the world. When it becomes possible for an individual to incur S$13.6 million in medical costs and S$1.25 million in taxi fares, it is inevitable that liability awards in those countries continue to rise.

Insurance brokers can sometimes make for gloomy dinner companions. Part of our job is to highlight to clients the scale of the risks they face, and how and where things could go wrong. Quite understandably, some of my clients respond with scepticism when I tell them that Asia is not the benign liability environment that it once was. They ask to see the proof. In my view, the Singapore High Court has just provided it.

Posted on: 23/02/2017 UTC+08:00


News

Beijing-based healthcare service platform Miaoshou Doctor has completed a ¥1.5 billion (US$232 million) Series F round of financing.
Chinese digital technology company, Xisoft Technology, which focuses on hospital operation management, has raised ¥100 million ($15.65 million) in Series A+ financing.
Hearing health company Olive Union has closed a $7M Series B round led by Beyond Next Ventures, Bonds Investment Groups and Japan Policy Finance Corporation.
Long Hill Capital, a venture capital firm in China, has closed on more than $300 million for its third fund on 15 March.
Eluminex Biosciences, an ophthalmic biotechnology company has completed a $50 million Series A financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
TVM Capital Healthcare, a global private equity and growth capital firm focused on emerging markets, has announced two team additions today.
In partnership with VeChain and DNV GL, Renji Hospital, a hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has launched the world's first blockchain-enabled intelligent tumour treatment centre.
Hong Kong-based BuyHive, a new global sourcing start-up that connects buyers with trusted verified overseas suppliers, has launched a PPE programme to help US companies optimise their post-Covid supply chains.



Analysis

L.E.K. Consulting’s Fabio La Mola tells HealthInvestor Asia about a healthcare market going through major changes – creating significant opportunities for investors in the region.
Edwin Tong, senior minister for health, explains how the Ministry of Health in Singapore is supporting the growth in the number of seniors with Alzheimer's.
Penny Wan, regional vice-president and general manager, Japan and APAC, Amgen, writes about the public health challenge of cardiovascular diseases.
French-based international ophthalmic optics company Essilor has signed Letters of Intent with the Royal Government of Bhutan and the Central Monastic Body to strengthen the country’s vision care infrastructure.
April Chang, country manager at Cigna Singapore, argues that wellness programmes at work can lead to reduced absenteeism, higher productivity and increased morale among employees.
Steven Fang understands how to set up a healthcare company. Not only is he chief executive and founder of ASX-listed oncology company Invitrocue, he was also the founder of Singapore-based Cordlife Group, a healthcare company which provides cord blood and cord lining banking services.
Imagine a world in which you can consult with your doctor via video. She asks for a blood sample, which can be collected and analysed from a device in your home. After that is diagnosed, the prescription is automatically sent to the pharmacy and Uber then picks it up. The time from diagnosis to drugs at your home is only 60 minutes.
The digitisation of health data through blockchain technology is a groundbreaking solution that will empower patients and provide them with better access to healthcare.


Podcasts

HealthInvestor Asia twitter feed










A Rolex Yacht-Master I Ladies Replica watch is basically a person watch that's crafted inside an identical fashion with a well-known maker¡¯s real piece. Purchasing Replica Watches seems as an excellent idea. Anyway,ON perfectcloneshop.com replica Rolex Yacht-Master Ladies watches are affordable, look almost the identical while using real ones and could easily acquired.